Navigation Links
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Date:12/4/2007

o develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , RARITAN, N.J., Dec. 4 ...ttention Deficit Hyperactivity Disorder (ADHD), sl...orbidities reported to occur more often in people ...sus those without an epilepsy diagnosis, according...cross the U.S. ,, Findings from " CNS-Related C...
(Date:12/3/2009)..., , MADISON, N.J., Dec. 3 /PRNewswire-Fir... patient,s risk of developing a potentially life-t...armaceutical therapies or chemicals is one of seve...ostics leader Quest Diagnostics (NYSE: DGX ) wil...tology (ASH) Annual Meeting and Exposition, Decemb...
(Date:12/3/2009)..., , WARRENDALE, Pa., Dec. 3 /PRN...demonstrated PACS* injection-record integration ca...of North America in Chicago. The Connect.PACS(TM...cs capabilities of its kind, is the latest release...rmatics Platform . ,, (Photo: http://www.ne...
Breaking Medicine Technology:Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 1Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 1Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 3
(Date:12/4/2009)...ec. 4 Care Investment T...) today announced that its Board of Directors has ...tock. The dividend is payable on December 22, 200... 2009. ,, About Care Investment Trust ,...stment and finance company investing in healthcare...
(Date:12/4/2009)...ISCO, Dec. 4 Medithrive, Inc. has ...pensary in the SF Bay Area by popular vote conduct...ite only three months in operation, the SF Bay com...ocation for accessing medicinal marijuana. ,,...rms the obvious: a dispensary which caters to the ...
(Date:12/4/2009)... Dec. 4 The American As...SA) applauds the Senate for ensuring that the Com...isions remain in the final health reform legislati...ing support to elders, people with disabilities an...ass a health care reform bill that will make it af...
(Date:12/4/2009)...TY, Mo., Dec. 4 The large, two-day...ciation of Free Clinics (NAFC) in Kansas City on W... also for anyone who is uninsured and has not seen... clinic will receive preventive primary care. ,...rge free clinic events this fall in Houston, New O...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chie...selected as a finalist for the "Chief Innovation O...iness with the power of cloud computing. Appy Awar...ve usage of Salesforce CRM or the Force.com platfo...heir sales, marketing, partner, service, support o...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
...oung people appear to be developing the most commo...a dramatic increase in the cost and suffering //ca... overexposure to ultraviolet light from the sun, u...almost always curable and that together afflict 1 ...
... years since the Transplantation of Human Organ Ac...ay with the programme. This has been due to variou...irection and the will to seriously consider this a...idney scandal there is a knee jerk reaction from v...
...ug Digoxin or Digitalis, which comes from the foxg...t efficiently by maintaining the rhythm of the hea...f the drug is changed by the team of researchers f... which works by changing the sugars attached to th...
...s have shown that the efficacy of low-carb diets c... researchers question whether raising protein inta...cent study researchers set out to test the hypothe...ight loss. However some are of the opinion that pr...
...se are crucial factors. But according to the resea...reventive Medicine, // it has been found that calo...ath by heart disease. The finding was based on... done from 1971 to 1975. The participants were gro...
...ould not be a factor in determining transplant el...hown that older heart transplant patients do just ...archers evaluated all 275 adult patients who recei...o 11 years following surgery. Results showed no st...
Other Medicine News:Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3Health News:Finding The Key To Weight Loss! 2
Plasmacup SC
Trabecular Metal Modular Acetabular System
BiHAPro Acetabular Cup
Gap II Revision Cup
Medicine Products: